Monarch Partners Asset Management LLC grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 11.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 303,550 shares of the biotechnology company's stock after purchasing an additional 31,125 shares during the period. Monarch Partners Asset Management LLC owned approximately 0.20% of Ironwood Pharmaceuticals worth $3,145,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of IRWD. Gladius Capital Management LP bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Banque Cantonale Vaudoise bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $58,000. Captrust Financial Advisors raised its holdings in shares of Ironwood Pharmaceuticals by 441.7% in the second quarter. Captrust Financial Advisors now owns 6,690 shares of the biotechnology company's stock worth $77,000 after buying an additional 5,455 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the first quarter worth approximately $78,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Ironwood Pharmaceuticals in the first quarter worth approximately $109,000.
Get Ironwood Pharmaceuticals alerts:Insiders Place Their Bets
In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 110,962 shares of the firm's stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the transaction, the chief executive officer now directly owns 712,440 shares in the company, valued at approximately $8,599,150.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 13.10% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Separately, StockNews.com downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 17th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $14.67.Ironwood Pharmaceuticals Trading Down 1.5 %
Shares of NASDAQ IRWD traded down $0.17 during midday trading on Wednesday, hitting $11.35. The company's stock had a trading volume of 47,029 shares, compared to its average volume of 2,067,859. The business's 50 day moving average is $11.88 and its two-hundred day moving average is $11.39. The firm has a market cap of $1.74 billion, a P/E ratio of 12.13 and a beta of 0.96. Ironwood Pharmaceuticals, Inc. has a 12-month low of $9.73 and a 12-month high of $12.95. The company has a current ratio of 25.78, a quick ratio of 25.78 and a debt-to-equity ratio of 0.67.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $108.64 million for the quarter, compared to the consensus estimate of $111.51 million. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%. As a group, equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.01 EPS for the current year.
Ironwood Pharmaceuticals Company Profile
(Get Rating)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Featured Articles
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
- Why is Ford up 8% In The Past Five Days?
- Monster Beverage Stock Still Looks Scary Good
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating).
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.